(Q39444104)

12 September 2017

title

Interaction of small molecule inhibitors of HIV-1 entry with CCR5. (English)

1 reference

12 September 2017

0 references

3

0 references

Thomas P Sakmar

14

0 references

author name string

Christoph Seibert

1

1 reference

12 September 2017

Weiwen Ying

2

1 reference

12 September 2017

Fotini Tsamis

4

1 reference

12 September 2017

Shawn E Kuhmann

5

1 reference

12 September 2017

Anandan Palani

6

1 reference

12 September 2017

Jayaram R Tagat

7

1 reference

12 September 2017

John W Clader

8

1 reference

12 September 2017

Stuart W McCombie

9

1 reference

12 September 2017

Bahige M Baroudy

10

1 reference

12 September 2017

Steven O Smith

11

1 reference

12 September 2017

Tatjana Dragic

12

1 reference

12 September 2017

John P Moore

13

1 reference

12 September 2017

language of work or name

English

0 references

publication date

21 February 2006

1 reference

12 September 2017

number of pages

14

1 reference

inferred from page(s)

published in

Virology

1 reference

12 September 2017

volume

349

1 reference

12 September 2017

issue

1

1 reference

12 September 2017

page(s)

41-54

1 reference

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

New developments in anti-HIV chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

T cell dynamics in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

An overview of the determinants of CCR5 and CXCR4 co-receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Comparison of helix interactions in membrane and soluble alpha-bundle proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

7 January 2021

V3: HIV's switch-hitter

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Development and evaluation of pharmacological agents targeting chemokine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Helix packing in polytopic membrane proteins: role of glycine in transmembrane helix association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

G-protein coupled receptors as allosteric machines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

New concepts in drug discovery: collateral efficacy and permissive antagonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

HIV fusion and its inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

HIV-1 entry inhibitors: evading the issue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

New targets for inhibitors of HIV-1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Discovery of a novel CCR3 selective antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Design, synthesis, and discovery of a novel CCR1 antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

HIV entry inhibitors in clinical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Crystal structure of rhodopsin: A G protein-coupled receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

New therapeutics that modulate chemokine networks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

The steric trigger in rhodopsin activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Structure and function of G protein-coupled receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

The family of G‐protein‐coupled receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

7 January 2021

A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

7 January 2021

Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

7 January 2021

Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

7 January 2021

Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.01.018

7 January 2021

10.1016/J.VIROL.2006.01.018

Identifiers

DOI

1 reference

12 September 2017

1 reference